Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Increases By 46.3%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 986,700 shares, a growth of 46.3% from the January 31st total of 674,300 shares. Based on an average daily volume of 295,700 shares, the short-interest ratio is currently 3.3 days. Approximately 4.7% of the shares of the stock are short sold.

MAIA Biotechnology Stock Performance

Shares of NYSEAMERICAN:MAIA traded down $0.05 during mid-day trading on Tuesday, reaching $1.65. The stock had a trading volume of 148,706 shares, compared to its average volume of 353,636. The company has a market cap of $43.16 million, a price-to-earnings ratio of -1.20 and a beta of 0.20. The stock has a 50 day moving average of $1.97. MAIA Biotechnology has a twelve month low of $1.27 and a twelve month high of $5.99.

Insider Activity at MAIA Biotechnology

In other news, Director Stan Smith purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were acquired at an average price of $1.87 per share, for a total transaction of $46,750.00. Following the completion of the acquisition, the director now directly owns 1,130,060 shares in the company, valued at approximately $2,113,212.20. The trade was a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 36.98% of the company’s stock.

Hedge Funds Weigh In On MAIA Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in MAIA Biotechnology during the 3rd quarter worth approximately $31,000. Geode Capital Management LLC boosted its holdings in shares of MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after buying an additional 35,821 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology during the fourth quarter worth $77,000. Institutional investors and hedge funds own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.